Its potential as an inducer of the non-amyloidogenic alpha-secretase ADAM10 has been subsequently demonstrated in primary cells, AD model mice, and a pilot study in human patients (38,39,51; Fig. 5A), indicating efficacy of the drug in mild to moderately affected patients51. The gene discussed is ADAM10; the disease is Alzheimer disease.